Acute Myeloid Leukemia (AML)
Conditions
Keywords
Retrospective, Non-interventional Study, FMS-like tyrosine kinase-3 (FLT3) mutations
Brief summary
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
Detailed description
The current study is a retrospective non-interventional study using real-world data collected from existing medical records to evaluate descriptively the treatment patterns and key healthcare resource use among AML patients with or without FLT3 mutation. The current study relies on secondary use of existing data, and there is no intervention involved. Patients who received the first AML treatment after the initial diagnosis, or were classified as relapsed/refractory (R/R), between January 1, 2013 and December 31, 2015 will be randomly selected to be included in this study, and the data from their existing medical records will be extracted. Eligible patients will be grouped based on FLT3 mutation status, intensive chemotherapy (IC) eligibility, and R/R status. For newly diagnosed patients, the index date will be defined as the initiation date of the first AML treatment following initial diagnosis. For the R/R patients, the index date will be defined as the date of the patient being classified as R/R. The study period will be the period from the index date to last follow-up date or death, whichever comes earlier. The endpoint measurements of this study are treatment patterns and key AML-related healthcare resources used during the study period.
Interventions
OTHERTreatment patterns among AML patients
This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
OTHERAML-related healthcare resources
This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
Sponsors
Astellas Pharma Global Development, Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of AML but NOT acute promyelocytic leukemia (APL) * Known FLT3 mutation status * Under the care of the participating physician during the past 3 years OR from the initial diagnosis of AML * The medical records related to AML for the patient are available to the physician and can be abstracted for this study * The medical records contains complete information on treatments and AML-related hospitalization, including admission date, length of stay, and reason of hospitalization * Initiation date of first treatment after AML diagnosis OR date of being classified as relapsed from or being refractory to initial treatment (R/R) is between January 1, 2013 and December 31, 2015
Exclusion criteria
* Not applicable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment patterns assessed by drugs initiated | Up to 3 years | — |
| Treatment patterns assessed by dosage | Up to 3 years | — |
| Treatment patterns assessed by duration of treatment | Up to 3 years | — |
| Treatment patterns assessed by whether remission was achieved. | Up to 3 years | — |
| Treatment patterns assessed by an event | Up to 3 years | Reported death, failure of treatment or relapse of any type |
| AML-related healthcare resource use assessed by number of hospitalizations and lengths of ICU hospital stay | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of emergency department (ED) visits | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of outpatient visits | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of blood transfusions | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of infections and associated treatments | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of lab tests | Up to 3 years | Lab tests include bone marrow biopsy |
| AML-related healthcare resource use assessed by number of relevant concomitant medications | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of diagnostic procedures | Up to 3 years | — |
| AML-related healthcare resource use assessed by use of mechanical ventilation | Up to 3 years | — |
| AML-related healthcare resource use assessed by use of parenteral feeding | Up to 3 years | — |
| AML-related healthcare resource use assessed by length of hospice care | Up to 3 years | — |
| AML-related healthcare resource use assessed by number of hospitalizations (ICU and non-ICU) | Up to 3 years | — |
| AML-related healthcare resource use assessed by lengths of hospital stay (ICU and non-ICU) | Up to 3 years | — |
Countries
United States
Outcome results
None listed